// App-Quantinova.ai

SAT0117 : SARILUMAB, A SUBCUTANEOUSLY-ADMINISTERED, FULLY-HUMAN MONOCLONAL ANTIBODY INHIBITOR OF THE IL-6 RECEPTOR: RELATIONSHIP BETWEEN EULAR RESPONSES AND CHANGE FROM BASELINE OF SELECTED CLINICAL PARAMETERS

Researchers

Presenter

  • M. C. Genovese

Principal Investigators

  • R. M. Fleischmann

  • S. Fiore

  • A. Radin

  • C. Fan

  • T. W. Huizinga

Medical Centers

  • Leiden University Medical Centre, Leiden, Netherlands

Locations

  • Netherlands

Companies

  • Regeneron Pharmaceut

  • Sanofi S.A.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Infant Respiratory Distress Syndrome

  • Ischemic stroke

  • Systemic inflammation

  • Rheumatoid arthritis

  • Neutropenia

  • Inflammatory Arthritis

  • Anemia

Biomarkers

  • Alanine transaminase

  • High sensitivity C-reactive protein

  • Interleukin 6

Drug/Treatment

  • Sarilumab

  • Ranitidine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved